Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial

In the Fondazione Italiana Linfomi MCL0208 phase 3 trial, lenalidomide maintenance (LEN) after autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL) improved progression-free survival (PFS) vs observation (OBS). The host pharmacogenetic background was analyzed to decipher whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrero, Simone, Grimaldi, Daniele, Arrigoni, Elena, Pironti, Mariapia, Zaccaria, Gian Maria, Alessandria, Beatrice, Genuardi, Elisa, De Luca, Gabriele, Ghislieri, Marco, Tavarozzi, Rita, Di Rocco, Alice, Re, Alessandro, Stefoni, Vittorio, Cavallo, Federica, Boccomini, Carola, Balzarotti, Monica, Zilioli, Vittorio, Moita, Filipa, Arcaini, Luca, Lucchini, Elisa, Ballerini, Filippo, Ferreri, Andrés J. M., Puccini, Benedetta, Palumbo, Giuseppe A., Galimberti, Sara, Cortelazzo, Sergio, Di Paolo, Antonello, Ladetto, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368781/
https://www.ncbi.nlm.nih.gov/pubmed/37058477
http://dx.doi.org/10.1182/bloodadvances.2022009504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368781/
https://www.ncbi.nlm.nih.gov/pubmed/37058477
http://dx.doi.org/10.1182/bloodadvances.2022009504

Ejemplares similares